A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

NCT01415102 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Phase 1
Single Dose
Safety
Toleration
Pharmacokinetics

Interventions

DRUG: PF-05212372
DRUG: PF-05212372
DRUG: PF-05212372
DRUG: PF-05212372
DRUG: Placebo
DRUG: PF-05212372
DRUG: PF-05212372
DRUG: PF-05212372
DRUG: Placebo

Sponsor

Pfizer